ATNM News and Press, Actinium Pharmaceuticals Inc. From 06/07/24

2024-06-07 07:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a meme frenzy, any positive news related to a company has a magnified impact on the stock price. In the euphoria of 2021, companies with ambitious growth plans skyrocketed. The markets didn&...

2024-05-21 09:13:41 ET More on Eli Lilly Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety Eli Lilly: Don't Overpay For Miracle Drugs Eli Lilly’s tirzepatide cleared for diabetes t...

2024-05-16 06:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity PR Newswire -  KOL and principal investigator, Dr. Farrukh Awan , Professor of Medicine, Division of Hematology Oncology at Univer...

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial PR Newswire ...

2024-05-13 18:15:03 ET Stephens analyst issues OVERWEIGHT recommendation for ATNM on May 13, 2024 04:22PM ET. ATNM was trading at $8.86 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendati...

2024-05-13 18:00:03 ET Sudan Loganathan from Stephens issued a price target of $25.00 for ATNM on 2024-05-13 16:22:00. The adjusted price target was set to $25.00. At the time of the announcement, ATNM was trading at $8.86. ATNM currently trades -10.65% versus its 52 wee...

Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting Actinium Announces Multiple Ab...

2024-05-12 09:32:38 ET Summary Actinium Pharmaceuticals is a late-stage biopharmaceutical company focused on developing radiotherapies for AML patients. The company's leading product candidate, Iomab-B, has shown promising results in clinical trials, increasing survival rates for ...

Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern PR Newswire Dr. Farrukh Awan , Professor of Medicine, Division of Hematology Oncology at...